热门资讯> 正文

Emergent BioSolutions签署CNJ-016合同修改授予

2025-07-09 05:25

Emergent BioSolutions(EBS) 0
Informatica Inc.(NYSE) 0

Emergent BioSolutions (NYSE:EBS) announced a modification to its contract to provide its smallpox vaccine, CNJ-016, to the Administration for Strategic Preparedness and Response, part of the U.S. Department of Health and Human Services.
The administration has opted to secure additional doses of this treatment under its existing 10-year contract, which addresses complications arising from smallpox vaccination.

More on Emergent Biosolutions

Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful
Emergent BioSolutions Inc. 2025 Q1 - Results - Earnings Call Presentation
Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript
Emergent biosolutions reaffirms 2025 revenue guidance of $750M-$850M amid turnaround progress
Emergent Biosolutions Q1 2025 Earnings Preview

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。